FDA accepts new drug application for Merck’s Doravirine/Islatravir
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
It is intended for contrast enhancement in MRI scans
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
Subscribe To Our Newsletter & Stay Updated